EFDID: 238831EFD: View Filing

Issuer: Bellerophon Therapeutics, Inc. (0001600132) - D

Accession: 0001600132-17-000054 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001600132
  • Entity Name:
    Bellerophon Therapeutics, Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    DELAWARE
  • Year of Inc:
    Within 5 years (2015)
  • Address:
    184 LIBERTY CORNER ROAD, SUITE 302
    WARREN, NJ 07059
  • Persons:
    Related Persons 15
    Fabian Tenenbaum
    Executive Officer, Director 
    Chief Executive Officer and Director
    Peter Fernandes
    Executive Officer 
    Chief Regulatory and Safety Officer
    Deborah Quinn
    Executive Officer 
    Chief Medical Officer
    Martin Dekker
    Executive Officer 
    Vice President of Engineering and Manufacturing
    Amy Edmonds
    Executive Officer 
    Vice President of Clinical Operations and Administration
    Parag Shah
    Executive Officer 
    Vice President of Business Operations
    Megan Schoeps
    Executive Officer 
    Controller and Principal Financial Officer
    Jonathan Peacock
    Director 
    Chairman of the Board
    Naseem Amin
    Director
    Scott Bruder
    Director
    Mary Ann Cloyd
    Director
    Jens Luehring
    Director
    Andre Moura
    Director
    Daniel Tasse
    Director
    Adam Weinstein
    Director
EDGAR: Offering Information
  • Accession Date:
    05/19/2017
  • First Sale Date:
    05/09/2017
  • Offering Amount:
    $1,612,500
  • Amount Sold:
    $1,612,500
  • Exemptions:
    Rule 506
  • Security Type(s):
EFD: Current State Notices

No State Notices found in EFD

EDGAR: Sales Compensation Recipient Information
RecipientCRDBroker DealerBD CRDStates
H.C. Wainwright & Co., LLC 375 None None All States
EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Bellerophon Therapeutics, Inc./s/ Fabian TenenbaumFabian TenenbaumChief Executive Officer and Director2017-05-18